Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTREPAD: Naproxen in pre-clinical Alzheimer's disease
NCT02702817Phase 2Completed
- Sponsor
- Douglas Mental Health University Institute
- Start
- Aug 2012
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Naproxen with Placebo (2 arms). Primary endpoint: Alzheimer Progression Score at 4 years. Started Aug 2012; status: completed.
02
Drugs
naproxen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02702817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702817.